Carregant...
Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical tria...
Guardat en:
| Publicat a: | Case Rep Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger AG
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8299391/ https://ncbi.nlm.nih.gov/pubmed/34326746 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000516404 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|